Your browser doesn't support javascript.
Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies.
Yan, Renhong; Wang, Ruoke; Ju, Bin; Yu, Jinfang; Zhang, Yuanyuan; Liu, Nan; Wang, Jia; Zhang, Qi; Chen, Peng; Zhou, Bing; Li, Yaning; Shen, Yaping; Zhang, Shuyuan; Tian, Long; Guo, Yingying; Xia, Lu; Zhong, Xinyue; Cheng, Lin; Ge, Xiangyang; Zhao, Juanjuan; Wang, Hong-Wei; Wang, Xinquan; Zhang, Zheng; Zhang, Linqi; Zhou, Qiang.
  • Yan R; Center for Infectious Disease Research, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, 18 Shilongshan Road, Hangzhou, Zhejiang, 310024, China.
  • Wang R; Institute of Biology, Westlake Institute for Advanced Study, 18 Shilongshan Road, Hangzhou, Zhejiang, 310024, China.
  • Ju B; Comprehensive AIDS Research Center and Beijing Advanced Innovation Center for Structural Biology, School of Medicine, and Vanke School of Public Health, Tsinghua University, Beijing, 100084, China.
  • Yu J; Tsinghua-Peking Joint Center for Life Sciences, Beijing, 100084, China.
  • Zhang Y; Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, 518112, China.
  • Liu N; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China.
  • Wang J; The Ministry of Education Key Laboratory of Protein Science, Beijing Frontier Research Center for Biological Structure, Beijing, 100084, China.
  • Zhang Q; Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Beijing, 100084, China.
  • Chen P; Collaborative Innovation Center for Biotherapy, Tsinghua University, Beijing, 100084, China.
  • Zhou B; School of Life Sciences, Tsinghua University, Beijing, 100084, China.
  • Li Y; Center for Infectious Disease Research, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, 18 Shilongshan Road, Hangzhou, Zhejiang, 310024, China.
  • Shen Y; Institute of Biology, Westlake Institute for Advanced Study, 18 Shilongshan Road, Hangzhou, Zhejiang, 310024, China.
  • Zhang S; Tsinghua-Peking Joint Center for Life Sciences, Beijing, 100084, China.
  • Tian L; The Ministry of Education Key Laboratory of Protein Science, Beijing Frontier Research Center for Biological Structure, Beijing, 100084, China.
  • Guo Y; Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Beijing, 100084, China.
  • Xia L; School of Life Sciences, Tsinghua University, Beijing, 100084, China.
  • Zhong X; Tsinghua-Peking Joint Center for Life Sciences, Beijing, 100084, China.
  • Cheng L; The Ministry of Education Key Laboratory of Protein Science, Beijing Frontier Research Center for Biological Structure, Beijing, 100084, China.
  • Ge X; Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Beijing, 100084, China.
  • Zhao J; School of Life Sciences, Tsinghua University, Beijing, 100084, China.
  • Wang HW; Comprehensive AIDS Research Center and Beijing Advanced Innovation Center for Structural Biology, School of Medicine, and Vanke School of Public Health, Tsinghua University, Beijing, 100084, China.
  • Wang X; Comprehensive AIDS Research Center and Beijing Advanced Innovation Center for Structural Biology, School of Medicine, and Vanke School of Public Health, Tsinghua University, Beijing, 100084, China.
  • Zhang Z; Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, 518112, China.
  • Zhang L; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China.
  • Zhou Q; Tsinghua-Peking Joint Center for Life Sciences, Beijing, 100084, China.
Cell Res ; 31(5): 517-525, 2021 05.
Article in English | MEDLINE | ID: covidwho-1139736
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Neutralizing monoclonal antibodies (nAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represent promising candidates for clinical intervention against coronavirus disease 2019 (COVID-19). We isolated a large number of nAbs from SARS-CoV-2-infected individuals capable of disrupting proper interaction between the receptor binding domain (RBD) of the viral spike (S) protein and the receptor angiotensin converting enzyme 2 (ACE2). However, the structural basis for their potent neutralizing activity remains unclear. Here, we report cryo-EM structures of the ten most potent nAbs in their native full-length IgG-form or in both IgG-form and Fab-form bound to the trimeric S protein of SARS-CoV-2. The bivalent binding of the full-length IgG is found to associate with more RBDs in the "up" conformation than the monovalent binding of Fab, perhaps contributing to the enhanced neutralizing activity of IgG and triggering more shedding of the S1 subunit from the S protein. Comparison of a large number of nAbs identified common and unique structural features associated with their potent neutralizing activities. This work provides a structural basis for further understanding the mechanism of nAbs, especially through revealing the bivalent binding and its correlation with more potent neutralization and the shedding of S1 subunit.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Cell Res Year: 2021 Document Type: Article Affiliation country: S41422-021-00487-9

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Cell Res Year: 2021 Document Type: Article Affiliation country: S41422-021-00487-9